AEON Biopharma Statistics
Total Valuation
AEON Biopharma has a market cap or net worth of $9.85 million. The enterprise value is $9.19 million.
| Market Cap | 9.85M |
| Enterprise Value | 9.19M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 49.88 million shares outstanding. The number of shares has increased by 613.82% in one year.
| Current Share Class | 49.88M |
| Shares Outstanding | 49.88M |
| Shares Change (YoY) | +613.82% |
| Shares Change (QoQ) | +24.42% |
| Owned by Insiders (%) | 17.68% |
| Owned by Institutions (%) | 26.14% |
| Float | 24.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 8.78 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.54
| Current Ratio | 0.54 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -141.53% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 1,389.39% |
| Weighted Average Cost of Capital (WACC) | 6.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$6.83M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.36% in the last 52 weeks. The beta is 0.64, so AEON Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -74.36% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 22.04 |
| Average Volume (20 Days) | 1,983,437 |
Short Selling Information
The latest short interest is 876,967, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 876,967 |
| Short Previous Month | 160,269 |
| Short % of Shares Out | 1.76% |
| Short % of Float | 3.65% |
| Short Ratio (days to cover) | 0.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.90M |
| Pretax Income | -54.62M |
| Net Income | -54.62M |
| EBITDA | -19.82M |
| EBIT | -19.90M |
| Earnings Per Share (EPS) | -$1.89 |
Balance Sheet
The company has $3.43 million in cash and $2.78 million in debt, with a net cash position of $656,000 or $0.01 per share.
| Cash & Cash Equivalents | 3.43M |
| Total Debt | 2.78M |
| Net Cash | 656,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | -15.36M |
| Book Value Per Share | -0.58 |
| Working Capital | -3.35M |
Cash Flow
| Operating Cash Flow | -13.64M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 78,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -13.64M |
| FCF Per Share | -$0.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AEON Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -613.82% |
| Shareholder Yield | -613.82% |
| Earnings Yield | -565.61% |
| FCF Yield | -141.26% |
Analyst Forecast
The average price target for AEON Biopharma is $1.43, which is 624.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1.43 |
| Price Target Difference | 624.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 26, 2025. It was a reverse split with a ratio of 1:72.
| Last Split Date | Feb 26, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:72 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |